EP2403839A4 - NEUROTROPHINE MIMETICS AND ITS USE - Google Patents

NEUROTROPHINE MIMETICS AND ITS USE

Info

Publication number
EP2403839A4
EP2403839A4 EP10749395.9A EP10749395A EP2403839A4 EP 2403839 A4 EP2403839 A4 EP 2403839A4 EP 10749395 A EP10749395 A EP 10749395A EP 2403839 A4 EP2403839 A4 EP 2403839A4
Authority
EP
European Patent Office
Prior art keywords
neurotrophin
mimetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10749395.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2403839A2 (en
Inventor
Frank M Longo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Us Government Represented By Department Of V
University of North Carolina at Chapel Hill
University of California
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of EP2403839A2 publication Critical patent/EP2403839A2/en
Publication of EP2403839A4 publication Critical patent/EP2403839A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP10749395.9A 2009-03-06 2010-03-05 NEUROTROPHINE MIMETICS AND ITS USE Withdrawn EP2403839A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15830609P 2009-03-06 2009-03-06
US16428209P 2009-03-27 2009-03-27
PCT/US2010/026372 WO2010102212A2 (en) 2009-03-06 2010-03-05 Neurotrophin mimetics and uses thereof

Publications (2)

Publication Number Publication Date
EP2403839A2 EP2403839A2 (en) 2012-01-11
EP2403839A4 true EP2403839A4 (en) 2014-05-28

Family

ID=42710232

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10749395.9A Withdrawn EP2403839A4 (en) 2009-03-06 2010-03-05 NEUROTROPHINE MIMETICS AND ITS USE

Country Status (4)

Country Link
EP (1) EP2403839A4 (enrdf_load_stackoverflow)
JP (2) JP2012519703A (enrdf_load_stackoverflow)
CA (1) CA2754570A1 (enrdf_load_stackoverflow)
WO (1) WO2010102212A2 (enrdf_load_stackoverflow)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2594318B1 (en) 2005-04-15 2020-06-10 University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
CA2780940C (en) 2009-11-12 2021-08-31 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CA2814540A1 (en) * 2010-10-13 2012-04-19 Horacio Uri Saragovi Inhibitors of p75 receptor and their uses
CN104995180A (zh) 2012-09-27 2015-10-21 特罗菲克斯制药股份有限公司 神经营养因子模拟化合物及其盐的结晶形式
EP3504209A4 (en) * 2016-08-25 2020-04-29 Pharmatrophix Inc. METHODS AND COMPOUNDS FOR THE TREATMENT OF ALCOHOL USE DISORDERS AND RELATED ILLNESSES
EP4355424A4 (en) * 2021-06-17 2025-04-30 Pharmatrophix, Inc. Methods and compositions for treating and managing alzheimer's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113097A2 (en) * 2005-04-15 2006-10-26 The University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
WO2008107365A1 (en) * 2007-03-02 2008-09-12 Medivir Ab New compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2762315B1 (fr) * 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
US6492380B1 (en) * 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
EA200400162A1 (ru) * 2001-07-11 2005-06-30 Элан Фармасьютикалз, Инк. N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения
IL161881A0 (en) * 2001-11-08 2005-11-20 Upjohn Co N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113097A2 (en) * 2005-04-15 2006-10-26 The University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
WO2008107365A1 (en) * 2007-03-02 2008-09-12 Medivir Ab New compounds

Also Published As

Publication number Publication date
EP2403839A2 (en) 2012-01-11
CA2754570A1 (en) 2010-09-10
JP2016026142A (ja) 2016-02-12
WO2010102212A2 (en) 2010-09-10
WO2010102212A3 (en) 2011-03-31
JP2012519703A (ja) 2012-08-30

Similar Documents

Publication Publication Date Title
NL350111I2 (nl) fenpicoxamid en prothioconazool
EP2203467A4 (en) POLYNUCLEOTIDES AND POLYPEPTIDES OF PHAGEN F-MRU AND APPLICATIONS THEREOF
EP2483292A4 (en) Variant LOV-D-POLYPEPTIDE AND ITS USES
EP2605789A4 (en) MODIFIED RELAXINPOLYPEPTIDES AND ITS USES
EP2646446A4 (en) Bromodomain inhibitors and uses thereof
EP2318429A4 (en) PROMININ-1 PEPTIDE FRAGMENTS AND ITS USE
EP2504439A4 (en) OPTIMIZED ENDONUCLEASE AND ITS USE
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
EP2493418A4 (en) BIODEGRADABLE WRAPPING AND ITS USE
EP2426110A4 (en) PYRAZOLYL-ACRYLNITRILE COMPOUNDS AND THEIR USES
EP2391714A4 (en) LIGATURE PROCEDURE AND ITS USE
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
DK3417701T3 (da) Genmodificerede mus og indpodning
EP2593463A4 (en) FORMULATIONS OF RIFAXIMINE AND APPLICATIONS THEREOF
EP2445894A4 (en) KETAL COMPOUNDS AND ITS USES
EP2432492A4 (en) APPLICATION AND USE OF PRG4 AND THERAPEUTIC MODULATION THEREOF
EP2489777A4 (en) CLOTH DRYER AND WASHING MACHINE DRYER
EP2476717A4 (en) POLYAMIDE AND POLYAMIDE COMPOSITION
EP3964184C0 (en) COMPRESSION GARMENTS AND COMPRESSION GARMENT SYSTEMS
EP2582836A4 (en) PRPK-TPRKB MODULATORS AND ITS APPLICATIONS
EP2489776A4 (en) CLOTH DRYER AND WASHING MACHINE DRYER
EP2672970A4 (en) FORMS OF RIFAXIMINE AND APPLICATIONS THEREOF
EP2491041A4 (en) BIVALENTE AND BIZYKLIC DIAZO-SMAC MIMETIKA AND ITS APPLICATIONS
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
EP2608785A4 (en) LIPOMA CYCLES AND ITS USES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111006

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140428

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 403/04 20060101ALI20140422BHEP

Ipc: A61K 31/4164 20060101ALI20140422BHEP

Ipc: A61K 31/5375 20060101ALI20140422BHEP

Ipc: A61K 31/522 20060101ALI20140422BHEP

Ipc: A61K 31/5377 20060101ALI20140422BHEP

Ipc: A61P 25/00 20060101ALI20140422BHEP

Ipc: C07D 473/02 20060101ALI20140422BHEP

Ipc: C07D 265/06 20060101AFI20140422BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Owner name: U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF V

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LONGO, FRANK, M.

Inventor name: MASSA, STEPHEN M.

17Q First examination report despatched

Effective date: 20150713

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160126